biotech firms expanding glp-1 use beyond diabetes and obesity 2025 Market Size, Scope, Forecast Report 2026 to 2035 Pharma Giants Bet on Next-Generation

The net benefit of GLP-1 receptor agonists in adults with overweight or obesity who do not have diabetes depends on their weight loss target and willingness to accept harms, according to researchers.Although GLP-1 receptor agonists have demonstrated effectiveness in reducing weight loss and risks for other chronic diseases, questions remain over whether the benefits outweigh the harms of the

Thats up 49% YoY and 155% from 2023

Or, the ingredients arent even listed sometimes

Semaglutide is designed for once-weekly dosing to maintain steady medication levels in your bloodstream

Stopping semaglutide often triggers weight regain within months

Semaglutide is the active ingredient in certain branded medications, including Wegovy and Ozempic